#### Check for updates

### **OPEN ACCESS**

EDITED BY Sulin Zhang, Huazhong University of Science and Technology, China

#### REVIEWED BY Yi Li, Beijing Tongren Hospital, Capital Medical University, China Yong Cui, Guangdong Provincial People's Hospital, China

\*CORRESPONDENCE Xin Ma ⊠ 13581709195@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

#### SPECIALTY SECTION

This article was submitted to Perception Science, a section of the journal Frontiers in Neuroscience

RECEIVED 21 October 2022 ACCEPTED 16 December 2022 PUBLISHED 10 January 2023

#### CITATION

Diao T, Chen Y, Jing Y and Ma X (2023) Clinical characteristics and prognosis of acute low-frequency hearing loss and ascending sensorineural sudden sensorineural hearing loss. *Front. Neurosci.* 16:1076109. doi: 10.3389/fnins.2022.1076109

#### COPYRIGHT

© 2023 Diao, Chen, Jing and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Clinical characteristics and prognosis of acute low-frequency hearing loss and ascending sensorineural sudden sensorineural hearing loss

### Tongxiang Diao<sup>†</sup>, Yurun Chen<sup>†</sup>, Yuanyuan Jing and Xin Ma\*

Department of Otolaryngology, Head and Neck Surgery, People's Hospital, Peking University, Beijing, China

**Objective:** The present study aimed to explore the pathogenesis of the ascending sudden sensorineural hearing (SSNHL) loss by comparing the clinical characteristics and prognosis of acute low-frequency hearing loss (ALFHL) and ascending SSNHL.

**Methods:** A total of 43 patients with ALFHL and 122 patients with ascending SSNHL were enrolled in this study. First, the prognosis of patients with ALFHL and ascending SSNHL were compared, and the prognostic factors of AFHL and ascending SSNHL were analyzed.

**Results:** Acute low-frequency hearing loss and ascending SSNHL have no remarkable difference in complete recovery rate. Compared to ascending SSNHL, ALFHL has younger onset age, female prevalence, lower hearing threshold, shorter time from onset to recovery, and a lower proportion of combined tinnitus. The PTA at admission and delay from onset to therapy were significantly related to the prognosis of patients with ascending SSNHL, while only delay from onset to therapy was significantly related to the prognosis of patients with ascending SSNHL and ALFHL recovered completely within 10 days from onset.

**Conclusion:** Audiogram shape plays a critical role in the prognosis of SSNHL. Ascending SSNHL and ALFHL may share a common pathological mechanism.

#### KEYWORDS

ALFHL, ascending SSNHL, audiogram shape, prognosis, related factors

## Introduction

Acute low-frequency sensorineural hearing loss (ALFHL) has been interpreted as an independent disease entity distinct from idiopathic sudden sensory neural hearing loss (SSNHL) (Imamura et al., 1997), characterized by low-frequency hearing loss, better prognosis, and high recurrence rate (Fuse et al., 2002). The diagnostic criteria for ALFHL

were as follows: (1) acute onset sensorineural hearing loss of > 30 dB at two consecutive low frequencies (250 and 500 Hz) within a period of 3 days; (2) 25 dB of normal hearing at hearing thresholds of 1, 2, 3, 4, and 8 kHz on the affected side; (3) 25 dB of normal hearing at hearing thresholds of 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz on the unaffected side; and (4) no history of episodic dizziness or spontaneous nystagmus (Jung et al., 2016). The pathophysiological mechanisms of ALHL are similar to those of sudden hearing loss; this phenotype has been associated with cochlear hydrops (CH) and early stages of Meniere's disease (Yamasoba et al., 1993). Due to the presence of helicotrema, hydrops begin at the apical turn of the cochlea, manifesting as low-frequency deafness, subsequently involving all frequencies with worsening hydrops (Thai-Van et al., 2001).

Sudden sensory neural hearing loss is defined as at least 30 dB sensorineural hearing loss in three sequential frequencies within 3 days with no identifiable cause (Stachler et al., 2012), which has an incidence ranging from 5 to 27/100,000 people in the Western countries and 19/100,000 in mainland China (Xie et al., 2020). The pathogenesis of SSNHL is yet unknown, although several hypotheses have been proposed, including viral infection, vascular compromise, membrane labyrinth hydrops, chronic inflammation, immunological diseases (Rossini et al., 2017), cochlear membrane rupture (Kuhn et al., 2011), inner ear cell stress reaction (Merchant et al., 2005), hemorrhage of the inner ear (Berrettini et al., 2013), and migraine (Hwang et al., 2018). Some studies have proposed that the SSNHL can be divided into four types of audiogram shapes based on the pattern of hearing loss: ascending, flat, profound, and descending. "Ascending or descending" referred to cases in which the average threshold of 0.25-0.5 kHz was 20 dB higher or lower than the average threshold of 4-8 kHz. When the difference in hearing threshold did not exceed 20 dB at any frequency, the audiogram shape was classified as "flat." For patients with a flat audiogram and hearing threshold >90 dB, the audiogram shape was classified as "profound." As shown previously, the ascending type has the best prognosis (Mattox and Simmons, 1977; Qian et al., 2018), with a recovery rate of about 83.33% (Li et al., 2016). The present study aimed to explore the pathogenesis of the ascending SSNHL by comparing the clinical characteristics and prognosis of patients with ALFHL.

## Materials and methods

# Study design and inclusion and exclusion criteria

This retrospective cohort study included 43 patients in line with the definition of ALFHL and 122 patients with ascending SSNHL hospitalized in our department for treatment from July 2015 to May 2018.

### Inclusion criteria

Ascending SSNHL group: (1) 18–70-year-old; (2) no gender requirement; (3) first-onset SSNHL; (4) unilateral hearing loss; (5) time from onset to treatment  $\leq$ 14 days; (6) the average threshold of 0.25–0.5 kHz was 20 dB higher than the average threshold of 4–8 kHz, and all frequency hearing thresholds were >25 dB; and (7) normal hearing or age-related hearing loss in the contralateral ear.

Acute low-frequency hearing loss group: (1) 18–70-yearold; (2) no gender requirement; (3) first-onset SSNHL; (4) unilateral hearing loss; (5) a time between onset and treatment  $\leq$ 14 days; (6) hearing loss of >30 dB at two consecutive low frequencies (250 and 500 Hz), but with 25 dB of normal hearing at hearing thresholds of 1, 2, 3, 4, and 8 kHz on the affected side; and (7) normal hearing or age-related hearing loss in the contralateral ear.

### **Exclusion criteria**

(1) Pregnancy or middle ear infections; (2) a definitive cause of deafness identified during treatment; (3) acoustic neuroma and other organic diseases; and (4) anxiety and insomnia.

### Treatment

After admission, treatments were applied in accordance with the Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association (2015). The systemic corticosteroids and hemodilution agents were administered as therapeutic measures. All patients received 40 mg of intravenous methylprednisolone for 5 consecutive days and hemodilution agents for 10 days, including 87.5 mg of intravenous EGb-761 (Ginkgo Biloba Extracts) (Dr. Willmar Schwabe GmbH & Co., Germany) daily.

### Efficacy evaluation

Pure-tone audiometry was performed at the initial presentation and 1 month after treatment. The pure-tone average of all frequencies (250, 500, 1,000, 2,000, 4,000, and 8,000 Hz) was employed to determine the treatment outcomes according to Siegel's (1975) criteria. Complete recovery (CR) indicated that the "final hearing level was <25 dB." Final hearing at 25–45 dB with a hearing gain of  $\geq$ 15 dB was "partial recovery." "Slight recovery" meant final hearing >45 dB with hearing gain of  $\geq$ 15 dB. The final hearing level >75 dB with hearing gain of  $\leq$ 15 dB represented "no recovery."

### Statement of ethics

This cohort research was approved by the Peking University People's Hospital Ethical permission committee (2021PHB149). Written informed consent for this research was received from each patient.

### Statistic

The clinical and epidemiological characteristics of the patients were summarized by descriptive statistics. The datasets were described with median and/or range. Numerical data were compared using *t*-test, and categorical data were compared using the  $\chi^2$  test. First, univariate analysis was used to compare the epidemiological and clinical characteristics of ALFHL and ascending SSNHL group, and then binary logistic regression analysis was used to analyze the prognostic factors of ALFHL and ascending SSNHL. The risk ratios were presented with 95% confidence interval (CI). Statistical significance was defined as a two-tailed P < 0.05 for all analyses. Statistical analyses were performed using SPSS software version 23.0 and GraphPad Prism 7.0.

### Results

# Clinical characteristics of ascending SSNHL and ALFHL

A total of 43 ALFHL patients and 122 patients with ascending SSNHL were enrolled in this study. Independent sample *t*-test and  $c^2$ -square test were used to compare the clinical characteristics and CR rate between patient groups with ascending SSNHL and ALFHL (**Table 1**). The statistical results showed statistical differences in age, gender, PTA at admission (the average hearing thresholds of 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 kHz), 1 kHz pure-tone threshold, 2 kHz pure-tone threshold, tinnitus occurrence, and the delay from onset to CR (onset-CR) between the two groups; however, the CR was not statistically different. Compared to the ascending SSNHL group, patients with ALFHL had a lower age of onset, lower PTA at admission, lower pure-tone threshold at 1 and 2 kHz, female tendency, shorter onset-CR time, and lower tinnitus incidence.

### Factors related to the prognosis of ALFHL

A total of 34/43 patients with ALFHL (79.07%) recovered completely. First, the univariate analysis showed that delay from onset to therapy (onset-therapy) was statistically related to the prognosis of patients with ALFHL. Then, onsettherapy and clinically significant factors, including age, PTA at admission, tinnitus, and dizziness, were included in the binary logistic regression analysis. The results showed that delay

| TABLE 1 Clinical characteristics of ascending sudden sensorineural |
|--|
| hearing loss (SSNHL) and acute low-frequency hearing loss (ALFHL). |

|                | Ascending<br>SSNHL ( <i>n</i> = 122) | ALFHL<br>(n = 43) | p      |
|----------------|--------------------------------------|-------------------|--------|
| Age            | $38.35 \pm 12.89$                    | $33.33 \pm 10.07$ | 0.011* |
| Sex (female)   | 62/122 (50.82%)                      | 31/43 (72.09%)    | 0.020* |
| Lateral (left) | 64/122 (52.46%)                      | 21/43 (48.84%)    | 0.725  |
| PTA (dB)       | $44.48 \pm 19.07$                    | $20.23 \pm 4.25$  | 0.000* |
| Tinnitus       | 111/122 (90.98%) 33/43 (76.74%)      |                   | 0.020* |
| Dizziness      | 18/122 (14.74%) 12/43 (27.91%)       |                   | 0.067  |
| Aural fullness | 63/122 (51.64%)                      | 25/43 (58.14%)    | 0.483  |
| Headaches      | 8/122 (6.56%)                        | 1/43 (2.33%)      | 0.448  |
| CR rate        | 84/122 (68.85%)                      | 34/43 (79.07%)    | 0.241  |
| UR rate        | 12/122 (9.84%)                       | 4/43 (9.30%)      | 1.000  |
| Onset-CR       |                                      |                   | 0.004* |
| 3 days         | 22/122 (18.03%)                      | 20/43 (46.51%)    |        |
| 3–7 days       | 38/122 (31.15%)                      | 7/43 (16.28%)     |        |
| 6-10 days      | 19/122 (15.57%)                      | 5/43 (11.63%)     |        |
| 10–14 days     | 5/122 (4.10%)                        | 1/43 (2.33%)      |        |
| 14-30 days     | 0/122 (0.00%)                        | 1/43 (2.33%)      |        |
| Un-CR          | 38/122 (31.15%)                      | 9/43 (20.93%)     |        |
| Onset-therapy  | Onset-therapy 3.41 ± 3.12            |                   | 0.920  |

CR, complete recovery; UR, un-recovery.

\*p < 0.05.

from onset-therapy was an independent related factor to the prognosis of ALFHL (Table 2).

### Factors related to the prognosis of ascending SSNHL

A total of 118/122 patients with ascending SSNHL (68.85%) completely recovered. First, the univariate analysis showed that delay from onset-therapy was statistically related to the prognosis of patients with ascending SSNHL. Then, onset-therapy and clinically significant factors, including age, PTA at admission, tinnitus, and dizziness, were included in the further binary logistic regression analysis. The results showed that PTA at admission and delay from onset-therapy were independent factors of the prognosis of ascending SSNHL (Table 3).

# Distribution of onset-CR of ALFHL and ascending SSNHL

The CR of ALFHL was 79.07% (34/43), of which 94.12% (32/34) were recovered within 10 days after onset. The CR of ascending SSNHL was 68.85% (84/122), which was slightly

| Variable                | Un-CR ( <i>n</i> = 9)                     | CR ( <i>n</i> = 34) | р      |  |
|-------------------------|---|---------------------|--------|--|
| Univariate analysis     |   |                     |        |  |
| Age                     | $37.67 \pm 10.559 \qquad 32.18 \pm 9.778$ |                     | 0.145  |  |
| Onset-therapy           | $6.44 \pm 4.613$                          | $2.68 \pm 1.788$    | 0.041* |  |
| PTA at admission        | $21.389\pm4.167$                          | $19.927\pm4.286$    | 0.365  |  |
| Gender (female)         | 6/9 (66.67%)                              | 25/34 (73.53%)      | 0.692  |  |
| Lateral (left)          | 5/9 (55.56%)                              | 16/34 (47.06%)      | 0.721  |  |
| Tinnitus                | 8/9 (88.89%)                              | 25/34 (73.53%)      | 0.659  |  |
| Dizziness               | 5/9 (55.56%)                              | 7/34 (20.59%)       | 0.088  |  |
| Aural fullness          | 6/9 (66.67%)                              | 19/34 (55.88%)      | 0.712  |  |
| Headache                | 1/9 (11.11%) 0/34 (0.00%)                 |                     | 0.209  |  |
| Multivariate analysis   |   |                     |        |  |
|                         | OR (95%CI)                                |                     | P      |  |
| Onset-therapy<br>(days) | 0.651 (0.463–0.915)                       |                     | 0.013* |  |

TABLE 2 Factors related to prognosis of acute low-frequency hearing loss (ALFHL).

\*p < 0.05.

TABLE 3 Factors related to prognosis of ascending sudden sensorineural hearing loss (SSNHL).

| Variable                | Un-CR<br>( <i>n</i> = 38)                  | CR ( <i>n</i> = 84) | p      |  |  |
|-------------------------|--|---------------------|--------|--|--|
| Univariate analysis     |  |                     |        |  |  |
| Age                     | $40.08 \pm 14.143 \qquad 37.57 \pm 12.283$ |                     | 0.322  |  |  |
| Onset-therapy           | $4.82 \pm 4.591$                           | $2.77 \pm 1.865$    | 0.011* |  |  |
| PTA at admission        | $46.84\pm19.723$                           | $43.414 \pm 18.785$ | 0.360  |  |  |
| Gender (female)         | 19/38 (50%)                                | 43/84 (51.19%)      | 0.903  |  |  |
| Lateral (left)          | 20/38 (52.63%)                             | 44/84 (52.38%)      | 0.980  |  |  |
| Tinnitus                | 36/38 (94.74%)                             | 75/84 (89.29%)      | 0.330  |  |  |
| Dizziness               | 7/38 (18.42%)                              | 11/84 (13.10%)      | 0.442  |  |  |
| Aural fullness          | 17/38                                      | 46/84               | 0.333  |  |  |
| Headache                | 1/38                                       | 7/84                | 0.433  |  |  |
| Multivariate and        | Multivariate analysis                      |                     |        |  |  |
|                         | OR (95%CI)                                 |                     | Р      |  |  |
| PTA at admission        | 0.981 (0.960-1.003)                        |                     | 0.092  |  |  |
| Onset-therapy<br>(days) | 0.781 (0.671–0.909)                        |                     | 0.001* |  |  |

\**p* < 0.05.

lower than that of ALFHL, albeit not significantly. Among them, 64.75% recovered within 10 days after the onset, accounting for 94.05% (79/84) of all recovered patients (**Figure 1**). Therefore, both ALFHL and ascending SSNHL were recovered within 10 days after onset, suggesting that both ALFHL and ascending SSNHL might lie in common pathogenesis. It also suggested that

one must have reasonable expectations of patients who have not completely recovered after 10 days from onset (Table 4).

## Discussion

The present study found that compared to ascending SSNHL, patients with ALFHL had a lower age of onset, lower PTA at admission, lower pure tone threshold at 1 and 2 kHz, female tendency, shorter time from onset to recovery, and a tinnitus incidence; however, the CR was not statistically different.

# No difference in the CR between ascending SSNHL and ALFHL

Several studies showed that audiogram shape is a major prognostic factor of SSNHL, divided into four clinical types: ascending, descending, flat, and profound (Chung et al., 2015). These factors guide the prognosis of patients with SSNHL.

Among all the four types, the ascending type has the best prognosis: 63-88% (Watanabe and Suzuki, 2018). Similarly, patients with ALFHL also showed a good prognosis. Typically, ALFHL has a better prognosis than SSNHL and responds well to treatment. Some studies reported that 32-65% of ALFHL patients recover their hearing spontaneously without treatment (Mattox and Simmons, 1977; Conlin and Parnes, 2007). Choo et al. (2017) found that about 70% of ALFHL patients treated with steroid therapy had recovered hearing. Nonetheless, whether ALFHL is an independent disease is yet controversial. Some studies considered ALFHL as a subtype of SSNHL, which has a better prognosis than other types (Shaia and Sheehy, 1976; Mattox and Simmons, 1977). In contrast, because of the good prognosis, high recurrence rate, ease of development into MD, and some other clinical characteristics, some studies classified it as a type of disease independent of SSNHL.

The results of this study did not present any significant difference in the CR between patients with ALFHL and ascending SSNHL. Compared to ascending SSNHL, patients with ALFHL were younger and with less severe hearing loss. In addition, ALFHL might be caused by various causes, among which CH is widely recognized (Noguchi et al., 2004; Junicho et al., 2008). It is illustrated that the apical turn of the cochlea is more sensitive to pressure changes than the basal turn; hence, the inner ear hydrops begins at the apical turn of the cochlea and subsequently extends to the cochlear aqueduct and the vestibular apparatus (7). Thus, ALFHL may be the early stage of ascending SSNHL; with aggravated inner ear hydrops, the degree of hearing loss is also aggravated and combined symptoms, resulting in tinnitus. The pathogenesis of ascending SSNHL is similar to ALFHL and might be related




TABLE 4 Distribution of onset-CR of patients with ascending sudden sensorineural hearing loss (SSNHL) and acute low-frequency hearing loss (ALFHL).

|                 |                      | 3 days | 3–7 days | 7–10 days | 10–14 days | 14–30 days |
|-----------------|----------------------|--------|----------|-----------|------------|------------|
| ALFHL           | Cases                | 20/43  | 7/43     | 5/43      | 1/43       | 1/43       |
|                 | CR rate              | 46.51% | 16.28%   | 11.63%    | 2.33%      | 2.33%      |
|                 | Cumulative frequency | 46.51% | 62.79%   | 74.42%    | 76.74%     | 79.07%     |
| Ascending SSNHL | Cases                | 22/122 | 38/122   | 19/122    | 5/122      | 0/122      |
|                 | CR rate              | 18.03% | 31.15%   | 15.57%    | 4.10%      | 0.00%      |
|                 | Cumulative frequency | 18.03% | 49.18%   | 64.75%    | 68.85%     | 68.85%     |

to CH (Junicho et al., 2008; Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association, 2015).

Furthermore, in view of the similar prognosis between ascending SSNHL and ALFHL, for patients with ascending SSNHL, partial treatment can be reduced, which is of great significance for optimizing medical resources. Because the etiology is usually unknown, treatments have been empiric (Wei et al., 2013). The lack of one or more uniformly accepted treatment(s) potentially decreases the cost of management.

# Factors related to the prognosis of ALFHL and ascending SSNHL

Factors affecting prognosis in patients with SSNHL include delay from onset-therapy, the occurrence of dizziness or tinnitus, type of audiogram, and initial hearing loss (Bespalova et al., 2001). Consistent with these findings, the current study showed that PTA at admission and delay from onset-therapy were independent factors related to the prognosis of ascending SSNHL. Many studies speculated that the earlier the patient receives treatment, the better the prognosis (Shaia and Sheehy, 1976; Byl, 1984). Byl (1984) demonstrated that when patients receive treatment within 7 days from onset, the recovery rate is 56%, while the recovery rate of patients who received treatment for >30 days after onset is only 27%. Shaia and Sheehy (1976) also proposed that the prognosis is improved when patients are treated within 30 days from onset. Moreover, the severity of hearing loss was a major prognostic factor. In the present study, the PTA at admission is an independent prognostic factor for patients with ascending SSNHL. Conversely, in patients with ALFHL, PTA at admission is not related to prognosis, which might be due to mild hearing loss. In the case of delay from onset to complete recovery, Sano et al. (1998) speculated that patients with hearing loss <70 dB at admission are likely to heal within 8 days, which is consistent with the results of this study, i.e., most patients with ascending sudden SSNHL and ALFHL recovered within 10 days (70.3%, 116/165).

### Limitations

Nevertheless, the present study also has some limitations. First, this retrospective analysis caused information bias in the statistical analysis. Second, this study collected patients with ascending SSNHL and ALFHL admitted to the hospital; however, several patients with ascending SSNHL, especially with ALFHL, would prefer to receive outpatient treatment because of mild hearing loss, causing a certain degree of selection bias. Third, the follow-up of this study was short, i.e., followed up to 1 month after treatment, making it impossible to collect data on the long-term prognosis and recurrence of patients with ascending SSNHL and ALFHL; these would be assessed in our follow-up studies.

## Conclusion

The PTA at admission and delay from onset-therapy were independent factors related to the prognosis of ascending SSNHL, while only the delay from onset-therapy was remarkably related to the prognosis of ALFHL. Audiogram shape is a prognostic factor of SSNHL; also, no statistical difference was observed in the CR rate between ALFHL and ascending SSNHL, which manifests as a similar audiogram shape, suggesting that ascending SSNHL and ALFHL share some common pathological mechanisms.

### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## **Ethics statement**

The studies involving human participants were reviewed and approved by the Peking University People's Hospital Ethical Permission Committee. The patients/participants provided their written informed consent to participate in this study.

## Author contributions

XM designed and conceptualized this study, interpreted the data, and revised the manuscript. TD, YC, and YJ designed and conceptualized study, collected and analyzed the data, and drafted the manuscript for intellectual content. All authors contributed to the article and approved the submitted version.

## Funding

This work was supported by the Peking University People's Hospital Scientific Research Development Funds (RDL2021–14 and RDY2021–25) and National Key Research and Development Program of China (2020YFC2005200).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### References

Berrettini, S., Seccia, V., Fortunato, S., Forli, F., Bruschini, L., Piaggi, P., et al. (2013). Analysis of the 3-dimensional fluid-attenuated inversionrecovery (3D-FLAIR) sequence in idiopathic sudden sensorineural hearing loss. *JAMA Otolaryngol. Head Neck Surg.* 139, 456–464. doi: 10.1001/jamaoto.2013. 2659

Bespalova, I. N., Van Camp, G., Bom, S. J., Brown, D. J., Cryns, K., DeWan, A. T., et al. (2001). Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. *Hum. Mol. Genet.* 10, 2501–2508. doi: 10.1093/hmg/10.22.2501

Byl, F. M. Jr. (1984). Sudden hearing loss: Eight years' experience and suggested prognostic table. *Laryngoscope* 94(5 Pt 1), 647–661.

Choo, O. S., Yang, S. M., Park, H. Y., Lee, J. B., Jang, J. H., Choi, S. J., et al. (2017). Differences in clinical characteristics and prognosis of sudden lowand high-frequency hearing loss. *Laryngoscope* 127, 1878–1884. doi: 10.1002/lary. 26382

Chung, J. H., Cho, S. H., Jeong, J. H., Park, C. W., and Lee, S. H. (2015). Multivariate analysis of prognostic factors for idiopathic sudden sensorineural hearing loss in children. *Laryngoscope* 125, 2209–2215. doi: 10.1002/lary.25196 Conlin, A. E., and Parnes, L. S. (2007). Treatment of sudden sensorineural hearing loss: II. A meta-analysis. *Arch. Otolaryngol. Head Neck Surg.* 133, 582–586. doi: 10.1001/archotol.133.6.582

Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association (2015). Guideline of diagnosis and treatment of sudden deafness (2015). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 50, 443–447.

Fuse, T., Aoyagi, M., Funakubo, T., Sakakibara, A., and Yoshida, S. (2002). Short-term outcome and prognosis of acute low-tone sensorineural hearing loss by administration of steroid. ORL J. Otorhinolaryngol. Relat. Spec. 64, 6–10. doi: 10.1159/000049079

Hwang, J. H., Tsai, S. J., Liu, T. C., Chen, Y. C., and Lai, J. T. (2018). Association of tinnitus and other cochlear disorders with a history of migraines. *JAMA Otolaryngol. Head Neck Surg.* 144, 712–717. doi: 10.1001/jamaoto.2018.0939

Imamura, S., Nozawa, I., Imamura, M., and Murakami, Y. (1997). Clinical observations on acute low-tone sensorineural hearing loss. Survey and analysis of 137 patients. *Ann. Otol. Rhinol. Laryngol.* 106, 746–750. doi: 10.1177/000348949710600906

Jung, A. R., Kim, M. G., Kim, S. S., Kim, S. H., and Yeo, S. G. (2016). Clinical characteristics and prognosis of low frequency sensorineural hearing loss without vertigo. *Acta Otolaryngol*. 136, 159–163. doi: 10.3109/00016489.2015.1094824

Junicho, M., Aso, S., Fujisaka, M., and Watanabe, Y. (2008). Prognosis of lowtone sudden deafness - does it inevitably progress to Meniere's disease? *Acta Otolaryngol.* 128, 304–308. doi: 10.1080/00016480601002096

Kuhn, M., Heman-Ackah, S. E., Shaikh, J. A., and Roehm, P. C. (2011). Sudden sensorineural hearing loss: A review of diagnosis, treatment, and prognosis. *Trends Amplif.* 15, 91–105. doi: 10.1177/1084713811408349

Li, F. J., Wang, D. Y., Wang, H. Y., Wang, L., Yang, F. B., Lan, L., et al. (2016). Clinical study on 136 children with sudden sensorineural hearing loss. *Chin. Med. J. (Engl.)* 129, 946–952. doi: 10.4103/0366-6999.179791

Mattox, D. E., and Simmons, F. B. (1977). Natural history of sudden sensorineural hearing loss. Ann. Otol. Rhinol. Laryngol. 86(4 Pt 1), 463-480. doi: 10.1177/000348947708600406

Merchant, S. N., Adams, J. C., and Nadol, J. B. Jr. (2005). Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. *Otol. Neurotol.* 26, 151–160. doi: 10.1097/00129492-200503000-00004

Noguchi, Y., Nishida, H., Tokano, H., Kawashima, Y., and Kitamura, K. (2004). Comparison of acute low-tone sensorineural hearing loss versus Meniere's disease by electrocochleography. *Ann. Otol. Rhinol. Laryngol.* 113(3 Pt 1), 194–199. doi: 10.1177/000348940411300304

Qian, Y., Zhong, S., Hu, G., Kang, H., Wang, L., and Lei, Y. (2018). Sudden sensorineural hearing loss in children: A report of 75 cases. *Otol. Neurotol.* 39, 1018–1024. doi: 10.1097/mao.00000000001891

Rossini, B. A. A., Penido, N. O., Munhoz, M. S. L., Bogaz, E. A., and Curi, R. S. (2017). Sudden sensorioneural hearing loss and autoimmune systemic diseases. *Int. Arch. Otorhinolaryngol.* 21, 213–223. doi: 10.1055/s-0036-1586162

Sano, H., Okamoto, M., Shitara, T., and Hirayama, M. (1998). What kind of patients are suitable for evaluating the therapeutic effect of sudden deafness? *Am. J. Otol.* 19, 579–583.

Shaia, F. T., and Sheehy, J. L. (1976). Sudden sensori-neural hearing impairment: A report of 1,220 cases. *Laryngoscope* 86, 389–398. doi: 10.1288/00005537-197603000-00008

Siegel, L. G. (1975). The treatment of idiopathic sudden sensorineural hearing loss. *Otolaryngol. Clin. North Am.* 8, 467–473.

Stachler, R. J., Chandrasekhar, S. S., Archer, S. M., Rosenfeld, R. M., Schwartz, S. R., Barrs, D. M., et al. (2012). Clinical practice guideline: Sudden hearing loss. *Otolaryngol. Head Neck Surg.* 146(Suppl. 3), S1–S35. doi: 10.1177/0194599812436449

Thai-Van, H., Bounaix, M. J., and Fraysse, B. (2001). Menière's disease: Pathophysiology and treatment. *Drugs* 61, 1089–1102. doi: 10.2165/00003495-200161080-00005

Watanabe, T., and Suzuki, M. (2018). Analysis of the audiogram shape in patients with idiopathic sudden sensorineural hearing loss using a cluster analysis. *Ear Nose Throat J.* 97, E36–E40. doi: 10.1177/014556131809 700706

Wei, B. P., Stathopoulos, D., and O'Leary, S. (2013). Steroids for idiopathic sudden sensorineural hearing loss. *Cochrane Database Syst. Rev.* 2013:Cd003998. doi: 10.1002/14651858.CD003998.pub3

Xie, W., Dai, Q., Liu, J., Liu, Y., Hellström, S., and Duan, M. (2020). Analysis of clinical and laboratory findings of idiopathic sudden sensorineural hearing loss. *Sci. Rep.* 10:6057. doi: 10.1038/s41598-020-63046-z

Yamasoba, T., Sugasawa, M., Kikuchi, S., Yagi, M., and Harada, T. (1993). An electrocochleographic study of acute low-tone sensorineural hearing loss. *Eur. Arch. Otorhinolaryngol.* 250, 418–422. doi: 10.1007/bf00180389